Bluestem is excited to see the addition of Dr. Srini Venkatesh, PhD, as Chief Scientific and Innovation Officer to the already strong team at TearClear.. Read the full story here
TearClear Corp. is an early-stage, disruptive eye health company focused on developing preservative-free topical ophthalmic drugs delivered from existing preserved, multi-dose systems. The company is developing a unique pharmaceutical platform to target chronic eye disease drugs where preservatives are commonly used to assure sterility in multi-dose bottles. TearClear aims to address the global market of ophthalmologic drugs for glaucoma, dry eye, allergic conjunctivitis and other indications
Shared by Tyler Stowater, board member of TearClear Corp.